Role of prebiotics and probiotics in the prevention of the gastrointestinal side effects of metformin among the type 2 diabetic patients

Sundus Khan; Hira Yousaf; Hina Rafiq; Zarish Zamir; Ayesha Muhammad Deen; Tayyab Mumtaz Khan; Hina Nauman; Sheema Nauman; Shahrukh Khan

doi:10.18203/2394-6040.ijcmph20232701

Authors

Sundus Khan Riphah International University, Islamabad, Pakistan
Hira Yousaf University of Huddersfield, United Kingdom
Hina Rafiq University of Agriculture Faisalabad, Punjab, Pakistan
Zarish Zamir University of Lahore, Pakistan
Ayesha Muhammad Deen University of Veterinary and Animal Sciences, Lahore, Pakistan
Tayyab Mumtaz Khan Rawalpindi Medical University, Rawalpindi, Pakistan
Hina Nauman Pir Mehr Ali Shah Arid Agriculture University, Rawalpindi, Pakistan
Sheema Nauman Pir Mehr Ali Shah Arid Agriculture University, Rawalpindi, Pakistan
Shahrukh Khan University of Veterinary and Animal Sciences, Lahore, Pakistan

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20232701

Keywords:

Prebiotics, Probiotics, Gastrointestinal, Side effects, Metformin, Type 2 diabetic patient

Abstract

Background: Diabetes mellitus (DM) is most common endocrine disorder all over the world. Metformin has been used as a first line drug, however, it has several gastrointestinal side effects. This study aims to determine the frequency of metformin induced gastrointestinal side effects among type 2 diabetic patients and role of prebiotics and probiotics in the prevention of the metformin-induced GI side effects.

Methods: This cross-sectional study was performed in a tertiary care hospital, Rawalpindi, among 130 for one year from January 2021 to December 2022. Data was collected by applying a self-structured questionnaire. Descriptive statistics were used for the data analysis. Data analysis was performed via statistical package for the social sciences (SPSS) version 25.0.

Results: The means for study variables like age, dose, and duration of therapy were 54.09 years, 1000 mg and 3.6 years respectively. Female patients had more GI side effects than male patients. Similarly, GI side effects frequency was also higher among the patients who were on metformin alone than the patients who were using metformin and combination of prebiotics and probiotics. Patients with higher dose of metformin and shorter duration of metformin therapy had higher frequency of GI symptoms. The most common GI symptom was constipation followed by diarrhea, bloating, abdominal pain, vomiting/nausea, dyspepsia, loss of appetite and flatulence.

Conclusions: Metformin induced GI symptoms were common among study population. Use of prebiotics and probiotics combination with metformin, low dose of metformin, and longer duration of metformin use were found protective against the metformin-induced GI side effects.

Metrics

Metrics Loading ...

References

Akhtar S, Khan Z, Rafiq M, Khan A. Prevalence of type II diabetes in District Dir Lower in Pakistan. Pak J Med Sci. 2016;32(3):622.

Sadeeqa S, Fatima M, Latif S, Afzal H, Nazir SU, Saeed H. Prevalence of metformin-induced gastrointestinal problems. Acta Poloniae Pharmaceutica-Drug Res. 2019;76(6):1073-7.

Iftikhar R, Qadir A, Iqbal Z, Usman H. Prevalence of vitamin B12 deficiency in patients of type 2 diabetes mellitus on metformin: a case control study from Pakistan. Pan Afr Med J. 2014;16(1).

Raveendran AV, Chacko EC, Pappachan JM. Non-pharmacological treatment options in the management of diabetes mellitus. Eur Endocrinol. 2018;14(2):31.

Tran L, Zielinski A, Roach AH, Jende JA, Householder AM, Cole EE, et al. Pharmacologic treatment of type 2 diabetes: oral medications. Ann Pharmacotherap. 2015;49(5):540-56.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429-42.

Feng J, Wang X, Ye X, Ares I, Lopez-Torres B, Martínez M, et al. Mitochondria as an important target of metformin: The mechanism of action, toxic and side effects, and new therapeutic applications. Pharmacol Res. 2022;106114.

Tarry-Adkins JL, Grant ID, Ozanne SE, Reynolds RM, Aiken CE. Efficacy and side effect profile of different formulations of metformin: a systematic review and meta-analysis. Diabetes Therap. 2021;12(7):1901-14.

Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes. 2015;64(5):1786-93.

Saluja M, Pareek KK, Swami YK. Study of Diversity of Metformin Related Gastrointestinal Side Effects. J Assoc Physicians India. 2020;68(8):36-8.

Yee SW, Lin L, Merski M, Keiser MJ, Gupta A, Zhang Y, et al. Prediction and validation of enzyme and transporter off-targets for metformin. J Pharmacokinetics Pharmacodynamics. 2015;42:463-75.

Dujic T, Zhou K, Tavendale R, Palmer CN, Pearson ER. Effect of serotonin transporter 5-HTTLPR polymorphism on gastrointestinal intolerance to metformin: a GoDARTS study. Diabetes Care. 2016;39(11):1896-901.

Burton JH, Johnson M, Johnson J, Hsia DS, Greenway FL, Heiman ML. Addition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels. J Diabetes Sci Technol. 2015;9(4):808-14.

McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426-35.

Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders. Diabetes Metab. 2011;37(2):90-6.

Dixon SA, Mishra S, Dietsche KB, Jain S, Mabundo L, Stagliano M, et al. The effects of prebiotics on gastrointestinal side effects of metformin in youth: A pilot randomized control trial in youth-onset type 2 diabetes. Front Endocrinol. 2023;14:424.

Coșoreanu A, Rusu E, Rusu F, Băleanu M, Cîrstea C, Marinescu M, et al. Probiotics and prebiotics in the prevention of gastrointestinal adverse reactions related to diabetes mellitus. Cytokines. 2021;10:13.

Lv Y, Zhao X, Guo W, Gao Y, Yang S, Li Z, Wang G. The relationship between frequently used glucose-lowering agents and gut microbiota in type 2 diabetes mellitus. J Diabetes Res. 2018;7.